

Press Release

Date: September 8, 2025

JUNTEN BIO Co., Ltd.

Masanari Kawaminami, President and CEO

JUNTEN BIO Announces Sponsored Research Agreement with Stanford University

JUNTEN BIO Co., Ltd. is pleased to announce the signing of a Sponsored Research Agreement with Stanford University in the United States. The principal investigators at Stanford Medicine are **Dr. Kazunari Sasaki**, clinical professor of surgery, and **Hiromitsu Nakauchi**, professor of genetics and member of Stanford Medicine's Institute for Stem Cell Biology and Regenerative Medicine. The collaboration will focus on the advancement of **induced T cell with suppressing function (iT_S) therapies** being developed by JUNTEN BIO.

Strategic Vision and Research Objectives

As part of our **global strategy to bring transformative regenerative medicine from Japan to the world**, JUNTEN BIO is launching this joint research with Stanford University. By combining our proprietary platform inducing immune tolerance with Stanford's clinical and scientific expertise, we aim to create new therapeutic options and accelerate a clear pathway toward clinical development in the United States.

- In collaboration with Dr. Sasaki, JUNTEN BIO is working to establish a novel manufacturing method for induced T cells by applying our immune tolerance-inducing technology to **cell therapy for deceased donor liver transplant recipients**.

- In a separate collaboration with Professor Nakauchi, JUNTEN BIO is conducting research to elucidate the detailed **immune tolerance mechanisms** of induced T cells with suppressing function (iT_S). These findings will provide the foundation for more advanced therapeutic control and broader clinical applications.

Together with Stanford University, JUNTEN BIO intends to leverage the outcomes of these joint research initiatives to generate data supporting an IND (Investigational New Drug) submission to the FDA and to advance clinical studies in the United States.

This collaboration represents a significant step forward in our mission to transform the future of transplant medicine. JUNTEN BIO looks forward to these efforts paving the way for groundbreaking advances in transplant medicine.

Contact Information:

JUNTEN BIO Co., Ltd.

Administration Department

Email: info@junttenbio.co.jp